Phase II study of Amrubicin in patients with Small-Cell Lung Cancer that is refractory or relapsed within 90 days of completing previous treatment (JCOG0901).
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2015
At a glance
- Drugs Amrubicin (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 04 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 18 Nov 2009 New trial record